Osaka et al. demonstrated that treatment with semaglutide leads to favorable changes in appendicular skeletal muscle mass among older adults with T2DM and HF, signifying potential for GLP-1 RAs to address sarcopenia [65]. The gene discussed is GLP1R; the disease is hydrops fetalis.